A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus)

BACKGROUND: Pembrolizumab (P) is an anti-PD-1 antibody that blocks the interaction between programmed cell death protein 1 (PD-1) on T-cells and PD-L1 and PD-L2 on tumour cells. A phase Ib trial of P plus chemotherapy was undertaken to evaluate the safety and efficacy. METHODS: Patients with advance...

Descripción completa

Detalles Bibliográficos
Autores principales: Weiss, Glen J, Waypa, Jordan, Blaydorn, Lisa, Coats, Jessica, McGahey, Kayla, Sangal, Ashish, Niu, Jiaxin, Lynch, Cynthia A, Farley, John H, Khemka, Vivek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520208/
https://www.ncbi.nlm.nih.gov/pubmed/28588322
http://dx.doi.org/10.1038/bjc.2017.145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520208/
https://www.ncbi.nlm.nih.gov/pubmed/28588322
http://dx.doi.org/10.1038/bjc.2017.145

Ejemplares similares